A number of studies in both adult and paediatric R/R ALL are underway, evaluating the efficacy of venetoclax in combination with chemotherapy, and/or navitoclax, a BCL-XL and BCL-2 inhibitor. Here, BCL2L1 is linked to acute lymphoblastic leukemia.